The absolute risk for SAEs with statin therapy is low. The estimated prevalence of CK levels greater than 10 × ULN with statin monotherapy is approximately 0.12%.24 In contrast, reports of SAEs with cerivastatin, alone and in combination with a fibrate or cyclosporine, were at least 20 times higher than with other statins, leading to the withdrawal of cerivastatin from the world market. The rate of myopathy noted in phase 2 and 3 clinical trials with cerivastatin was based on lower dosages than those used in phase 4 trials. Higher dosages (0.4 mg/d and 0.8 mg/d) were also often used in clinical practice, and despite clearly specified warnings in the product label and letters sent to physicians, cerivastatin was often prescribed in combination with a fibrate.5,33,34,70,119- 124 In the AERS data reported by Staffa and colleagues,5 cerivastatin was associated with 3.16 reports of fatal rhabdomyolysis per 1 million prescriptions (approximately 0.63 deaths per 100 000 patient-years, based on a hypothetical average prescription duration of 6 months), whereas for lovastatin, simvastatin, atorvastatin, pravastatin, and fluvastatin, the rates were 0.19, 0.12, 0.04, 0.04, and 0.0 cases, respectively, per 1 million prescriptions (approximately 0.04, 0.02, 0.01, 0.01, and 0.00 deaths, respectively, per 100 000 patient-years). However, as we begin to treat more patients with high global risk, risk for SAEs is likely to increase because of factors such as increased age and multiple therapies.